I'm the founder of IPO Edge, an in-depth research service for IPOs on US markets. As CEO of VentureDeal, a North American venture capital database, I've researched pre- and post-IPO companies for years. Subscribers to IPO Edge receive access to my proprietary data, valuation, commentary and opinions on all U.S. IPOs. Join now and become a member of the exclusive IPO Edge community, where you'll get an "insider's edge" on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.
I am an investor with a background in biotechnology and genetics. My Ph.D. education and professional experience are focused on genetics, stem cells, CRISPR, next generation sequencing and gene therapy. My investments and investment ideas are focused on long plays on under-appreciated/revolutionary products at the cutting edge of science.
Clover Biotech Research is headed by Stephen Ayers. Currently, we are featuring our Lucky Seven swing-trading portfolio of biotechnology stocks that present with excellent short-term risk-to-reward ratios. Because we believe in simplicity and not overwhelming readers with dozens of ideas, the portfolio is designed in a way to reflect both risk-tolerance and our top three picks. We will also occasionally present long-term ideas, research, technical analysis, etc. Stephen is a Registered Nurse who works on an intermediate care unit in a hospital and witnesses first-hand the powerful impact of medicine. He is an avid biotechnology researcher and advocater. He believes collaboration with persons of differing biotechnology angles will enrich his work. Subsequently, he has formed Clover Biotech Research to provide a platform for investors to experience several different perspectives. Clover recently welcomed Gobinath Varadappan, a biomedical engineer with big pharma experience and knowledge of clinical, regulatory, and commercial aspects of drug development. Gobinath is looking forward to making vital contributions to the team. Clover plans to secure additional advisers and writers in the future.
Our news team's weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks.
The Insiders Forum focus is on small and mid-cap stocks that insiders are buying. Some studies have shown that equities with heavy insider purchases outperform the overall market over time. The portfolio managed by Bret Jensen consists of 15-20 top stocks in different sectors of the market that not only are attractively valued but have had some significant insider purchases in recent months. Our goal is to outperform the Russell 2000 (the benchmark) over time. The Insiders Forum is also a sounding board for new investments in attractively priced equities where insiders are stepping up to the plate.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace Offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
SA PRO author & marketplace contributor. Successful PRO calls include $AKAO (+400% within 6 months) & $MRNS (+450% within 6 months).
I am providing members of my marketplace service, 'Second-Level Investing' with exclusive ideas, analysis and interviews with managers and subject matter experts.
- A former diplomat & entrepreneur. A former Project Manager at UN Principles for Responsible Investment
- An alumni of SciencesPo Paris
- Based in Luxembourg
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.